Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
4 rezilta yo
A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
A placebo controlled, randomised, parallel group, multicentre trial conducted in accordance with the guidelines of Good Clinical Practice (GCP) shows the efficacy and safety of a standardised extract of fresh berries of Crataegus oxyacantha L. and monogyna Jacq. (Crataegisan) in patients with
[Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure].
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Standardized extracts of Crataegus leaves and blossoms are said to have positive inotropic, positive dromotropic and negative bathmotropic effects. Clinical trials produce evidence for an improvement of symptoms in patients with congestive heart failure (NYHA II). In this trial the efficacy of a
Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure--a pooled analysis of clinical trials.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
The efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of
[High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure].
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The efficacy and tolerance of the standardized hawthorn (crataegus) extract WS 1442 were tested in a multicenter utilization observational study. We monitored 1,011 patients with cardiac insufficiency stage NYHA II, treated with this extract (Crataegutt novo 450, 1 tablet b.i.d.) over a period of 24
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
